NXTC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	100 435
Average Volume	283 117
Market Cap	40.28M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.450 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.640
ATR14	$0.0120 (0.84%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Shaw Kevin G.	Buy	93 900	Employee Stock Option (Right to Buy)
2024-03-29	Richman Michael	Buy	244 400	Employee Stock Option (Right to Buy)
2024-03-29	Myint Han	Buy	93 900	Employee Stock Option (Right to Buy)
2024-03-29	Mayer Timothy	Buy	93 900	Employee Stock Option (Right to Buy)
2024-03-29	Langermann Sol	Buy	93 900	Employee Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 6 167 538 \| Sell: 82 463

Volume Correlation

Long: -0.06 (neutral)

Short: 0.96 (very strong)

Signal:(42.469) Expect same movement, but be aware

NextCure Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NextCure Inc Correlation - Currency/Commodity

-0.09
( neutral )

-0.26
( neutral )

0.00
( neutral )

-0.27
( neutral )

-0.65
( moderate negative )

0.06
( neutral )

NextCure Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3.68M (0.00 %)
EPS:	$-2.25

Q4	2023
Revenue:	$0
Gross Profit:	$-824 000 (0.00 %)
EPS:	$-0.520

Q3	2023
Revenue:	$0
Gross Profit:	$-946 000 (0.00 %)
EPS:	$-0.510

Q2	2023
Revenue:	$0
Gross Profit:	$-1.09M (0.00 %)
EPS:	$-0.640

Financial Reports:

No articles found.

NextCure Inc

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.